Sustaining the effort for cancer prevention.

The Cancer Research Foundation of America has played a key role in "fueling the engine" of cancer prevention progress through a national research grant and education program. It is one of the nation's leading cancer prevention organizations, and has helped move prevention science from the fringes to the mainstream. Since its inception in 1985, it has provided more than $42.1 million in funding for cancer prevention research and education. It has supported pioneering research and translated it into practical information to educate men, women, and children about how to reduce their cancer risk. As more and more research results in practical interventions to prevent cancer, the Foundation will continue to act in an anticipatory way to help smooth the way for rapid translation of information from scientific study to consumer information through education and awareness initiatives. As we celebrate our 15th anniversary, the Cancer Research Foundation of America has recommitted itself to its role as a catalyst for change. It hopes to help the nation move toward a future in which harsh and often toxic treatment for cancer is replaced with a sane policy of cost-effective early intervention-healthy lifestyle education, detection of premalignant conditions, and therapies that spare healthy tissue. The Foundation believes there is a groundswell of support for making cancer prevention and early detection a national priority.

Evaluation of sodium L-thyroxine (T4) requirement in replacement therapy of hypothyroidism.

Sodium-L-thyroxine (T4) was utilized in the treatment of 15 pediatric patients with hypothyroidism. Adequacy of replacement therapy was confirmed by clinical evaluation in conjunction with determination of serum thyroxine, tri-odothyronine, and thyrotropin concentrations. Daily dose of thyroxine capable of including clinical and biochemical euthyroidism ranged from 2.5 to 5 mug/kg of body weight with a mean of 3.5 +/- 0.3 mug in the 4- to 17-year-old age group. Two infants with congenital hypothyroidism diagnosese observations imply that physiologic requirements of thyroxine are distinctly lower than previously recommended dosages. Further studies to establish more precise therapeutic guidelines are needed.